Trial · NCT06468943
Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL
NCT06468943, Phase 2, Enrolling by invitation, The First Affiliated Hospital of Soochow University
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL. Trials, record NCT06468943. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06468943
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL
- NCT number
- NCT06468943
- Status
- Enrolling by invitation
- Phases
- Phase 2
- Enrollment
- 20 participants, estimated
- Lead sponsor
- The First Affiliated Hospital of Soochow University
- Conditions
- Effects of Chemotherapy, Safety Issues
- Interventions
- Polatuzumab Vedotin, Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone
- First posted
- 2024-06-21
- Last updated
- 2024-06-21
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free Survival（PFS） | From date of enrollment until the date follow up for 2 years after the treatment or progression disease or date of death for any cause. | The time between enrollment and tumor occurrence (in any aspect) progression or (for any reason) death |
| Secondary | Objective Response rate（ORR） | From date of enrollment until the date follow up for 2 years after the treatment or progression disease or date of death for any cause. | The proportion of patients who achieved complete or partial response in efficacy evaluation at the end of treatment |
| Secondary | Complete Response（CR） | From date of enrollment until the date follow up for 2 years after the treatment or progression disease or date of death for any cause. | The proportion of patients who achieved complete response in efficacy evaluation at the end of treatment |
| Secondary | Duration of Response（DOR） | All time in the study | It refers to the time from the first assessment of a tumor as CR or PR to the second assessment as PD (Progressive Disease) or death from any cause. |
| Secondary | Overall Survival | From date of enrollment until the date follow up for 2 years after the treatment or progression disease or date of death for any cause. | The time between enrollment to death(for any reason) . |
| Secondary | Adverse Events(AEs) | From date of enrollment until the date follow up for 2 years after the treatment or progression disease or date of death for any cause. | All treatment-related adverse events that occur during patient treatment and follow-up. |
| Other | Exploratory study endpoint | From date of enrollment until the date follow up for 2 years after the treatment or progression disease or date of death for any cause. | Exploring the therapeutic response of subjects with different genotypes to Pola+ZR-CHP regimen using Next-generation sequencing(NGS). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06468943
GET https://conductscience.org/api/trials/v1/NCT06468943/registered